News Image

NASDAQ:GMAB, a strong growth stock, setting up for a breakout.

By Mill Chart

Last update: Feb 8, 2024

Exploring Growth Potential: GENMAB A/S -SP ADR (NASDAQ:GMAB) and Its Base Formation. Growth investors seek promising revenue and EPS growth, and GENMAB A/S -SP ADR has come under our scrutiny for potential growth investing. While it's crucial to do your own research, we've detected GENMAB A/S -SP ADR on our screen for growth with base formation, suggesting it merits a closer look.

Growth Examination for NASDAQ:GMAB

ChartMill assigns a Growth Rating to each stock, ranging from 0 to 10. This rating is determined by analyzing different growth elements, including EPS and revenue growth, spanning both historical and future figures. In the case of NASDAQ:GMAB, the assigned 8 reflects its growth potential:

  • The Earnings Per Share has been growing by 36.32% on average over the past years. This is a very strong growth
  • GMAB shows a strong growth in Revenue. In the last year, the Revenue has grown by 42.01%.
  • The Revenue has been growing by 43.90% on average over the past years. This is a very strong growth!
  • The Earnings Per Share is expected to grow by 19.39% on average over the next years. This is quite good.
  • Based on estimates for the next years, GMAB will show a very strong growth in Revenue. The Revenue will grow by 73.04% on average per year.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

Evaluating Health: NASDAQ:GMAB

ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NASDAQ:GMAB has earned a 8 out of 10:

  • An Altman-Z score of 21.22 indicates that GMAB is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 21.22, GMAB belongs to the best of the industry, outperforming 93.56% of the companies in the same industry.
  • The Debt to FCF ratio of GMAB is 0.14, which is an excellent value as it means it would take GMAB, only 0.14 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of GMAB (0.14) is better than 97.12% of its industry peers.
  • GMAB has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • Even though the debt/equity ratio score it not favorable for GMAB, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
  • GMAB has a Current Ratio of 11.38. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
  • GMAB's Current ratio of 11.38 is amongst the best of the industry. GMAB outperforms 80.17% of its industry peers.
  • A Quick Ratio of 11.36 indicates that GMAB has no problem at all paying its short term obligations.
  • The Quick ratio of GMAB (11.36) is better than 80.34% of its industry peers.

Profitability Assessment of NASDAQ:GMAB

ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:GMAB, the assigned 7 is noteworthy for profitability:

  • GMAB has a better Return On Assets (12.19%) than 97.97% of its industry peers.
  • Looking at the Return On Equity, with a value of 13.81%, GMAB belongs to the top of the industry, outperforming 96.78% of the companies in the same industry.
  • The Return On Invested Capital of GMAB (15.04%) is better than 98.14% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for GMAB is above the industry average of 13.61%.
  • Looking at the Profit Margin, with a value of 25.24%, GMAB belongs to the top of the industry, outperforming 97.97% of the companies in the same industry.
  • GMAB has a better Operating Margin (37.10%) than 98.64% of its industry peers.

Looking at the Setup

Besides the Technical Rating, ChartMill assigns a Setup Rating to every stock to determine the degree of consolidation. This rating, ranging from 0 to 10, is updated daily and evaluates various short-term technical indicators. NASDAQ:GMAB currently holds a 8 as its setup rating, suggesting a particular level of consolidation in the stock.

GMAB has a bad technical rating, but it does show a decent setup pattern. Prices have been consolidating lately and the volatility has been reduced. There is a resistance zone just above the current price starting at 27.98. Right above this resistance zone may be a good entry point. There is a support zone below the current price at 27.80, a Stop Loss order could be placed below this zone. We notice that large players showed an interest for GMAB in the last couple of days, which is a good sign.

Every day, new Strong Growth stocks can be found on ChartMill in our Strong Growth screener.

Our latest full fundamental report of GMAB contains the most current fundamental analsysis.

Our latest full technical report of GMAB contains the most current technical analsysis.


Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.



NASDAQ:GMAB (4/18/2024, 7:00:02 PM)

Premarket: 28 -0.33 (-1.16%)


-0.2 (-0.7%)


News Image8 days ago - ChartmillNASDAQ:GMAB is not too expensive for the growth it is showing.

While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.

News Image16 days ago - Investor's Business DailyGenmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio

Genmab is buying a privately held company focused on antibody drug conjugates.

News Image16 days ago - Genmab A/SGenmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
News Image2 months ago - Genmab A/SU.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
News Image2 months ago - Seeking AlphaAbbVie/ Genmab win FDA priority review for lymphoma therapy (NYSE:ABBV)

Genmab (GMAB) and AbbVie (ABBV) win FDA priority review for a marketing application to expand the label for their bispecific antibody epcoritamab-bysp. Read more here.

News Image2 months ago - Seeking AlphaBMO upgrades Genmab to outperform, cites diversification potential (NASDAQ:GMAB)

BMO has upgraded Genmab (GMAB) to outperform, stating that it was “incrementally more confident” in the company’s ability to diversify its business longer term

News Image2 months ago - Seeking AlphaGenmab reports FY results (NASDAQ:GMAB)

Genmab reports a FY operating profit of DKK 5,321 million in 2023, with revenue reaching DKK 16.47B, driven by successful collaborations and strong product...

News Image3 months ago - Seeking AlphaPfizer-Genmab cervical cancer drug gets accepted for EU review (NYSE:PFE)

Pfizer (PFE) and Genmab (GMAB) announced on Friday the marketing application for its cervical cancer antibody-drug conjugate ((ADC)) has been validated for revi

GMAB Links
Follow us for more